Bristol‑Myers Squibb (BMS, NYSE: BMY) announced positive topline results from the Phase 3 SCOUT‑HCM study evaluating mavacamten in adolescent patients (aged 12 to <18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking the first cardiac myosin inhibitor (CMI) study in this population.
Contents
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Bristol‑Myers Squibb (NYSE: BMY) |
| Drug | Mavacamten (cardiac myosin inhibitor) |
| Study | Phase 3 SCOUT‑HCM |
| Population | Adolescents (12‑<18 years) with symptomatic oHCM |
| Enrollment | 44 patients |
| Primary Endpoint | Reduction from baseline in LVOT gradient with Valsalva maneuver at Week 28 |
| Key Secondary Endpoints | Multiple clinically meaningful disease assessment measures |
| Safety Profile | Consistent with adult population; no new safety signals |
| Study Status | Treatment period and long‑term extension ongoing |
Drug Profile & Mechanism of Action
- Mechanism: Cardiac myosin inhibitor (CMI) that reduces myocardial contractility and LVOT obstruction without compromising cardiac output
- Global Registration: Approved in over 50 countries and regions across five continents for adult oHCM
- Innovation: First CMI studied in adolescent oHCM population, addressing a critical unmet need
- Clinical Significance: Demonstrates effective improvement in LVOT obstruction, a key pathophysiological feature of oHCM
Clinical Evidence – Phase 3 SCOUT‑HCM
| Endpoint | Mavacamten | Placebo | Statistical Significance |
|---|---|---|---|
| Primary: LVOT Gradient Reduction (mmHg) | Statistically significant | Baseline | p < 0.001 |
| Secondary Endpoints | Multiple achieved | – | p < 0.05 |
| Safety (Grade ≥ 3 TEAEs) | Consistent with adult profile | – | No new signals |
| Enrollment Completion | 44 adolescent patients | – | – |
Market Opportunity & Competitive Landscape
| Parameter | China | Global |
|---|---|---|
| Adolescent oHCM Prevalence | 8,500 | 45,000 |
| Diagnosed & Symptomatic | 3,400 | 18,000 |
| Current Standard | Beta‑blockers, calcium channel blockers, surgical myectomy | |
| Pharmacologic Options | None specifically approved for adolescents | None specifically approved for adolescents |
| Mavacamten Addressable Market | 3,400 | 18,000 |
| Peak Market Penetration | 0 % | 25 % |
| Annual Cost (USD) | – | $85,000 |
| Peak Revenue (2030E) | – | $382 million |
- Competitive Gap: No FDA‑approved pharmacologic therapy specifically for adolescent oHCM; mavacamten would be first‑in‑class
- Next Steps: J&J plans sNDA submission to FDA in Q2 2026; potential PDUFA date Q1 2027
Strategic Positioning
- Manufacturing: Established global supply chain with three production sites capable of supporting pediatric population
- Commercial Readiness: Existing cardiology sales force can seamlessly expand to adolescent indication
- Regulatory Pathway: Breakthrough Therapy Designation likely given first‑in‑class status and unmet need
- Pipeline Expansion: Data supports potential expansion to pediatric population (age 8‑12) and non‑obstructive HCM
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory submissions, commercial forecasts, and market penetration for mavacamten in adolescent oHCM. Actual results may differ due to FDA review outcomes, competitive dynamics, and market access challenges.-Fineline Info & Tech
